Johnson & Johnson $JNJ Shares Bought by Moloney Securities Asset Management LLC

Key Points

• Moloney Securities Asset Management LLC increased its stake in Johnson & Johnson shares by 4.2% during Q2, holding 37,079 shares valued at approximately $5.66 million.
• Insider selling at Johnson & Johnson saw EVP Jennifer L. Taubert selling over 56,000 shares, which represented a 24.08% decrease in her ownership.
• Analysts have recently upgraded Johnson & Johnson stock, with Daiwa America raising its rating from "hold" to "strong-buy" and a consensus rating shifting to a "Moderate Buy".

Moloney Securities Asset Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,079 shares of the company's stock after buying an additional 1,510 shares during the period. Johnson & Johnson accounts for 0.7% of Moloney Securities Asset Management LLC's investment portfolio, making the stock its 25th largest position. Moloney Securities Asset Management LLC's holdings in Johnson & Johnson were worth $5,664,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Greenup Street Wealth Management LLC raised its position in Johnson & Johnson by 3.1% in the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company's stock valued at $309,000 after purchasing an additional 60 shares in the last quarter. Ellis Investment Partners LLC raised its position in Johnson & Johnson by 0.7% in the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock valued at $1,307,000 after purchasing an additional 62 shares in the last quarter. Cypress Wealth Services LLC raised its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock worth $1,013,000 after acquiring an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN lifted its stake in Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock worth $97,000 after purchasing an additional 64 shares during the last quarter. Finally, Global Strategic Investment Solutions LLC boosted its holdings in Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock valued at $294,000 after purchasing an additional 65 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on JNJ. Daiwa America raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Monday, October 20th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an "overweight" rating in a report on Friday, October 3rd. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a report on Thursday, October 9th. Finally, Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $199.05.

Johnson & Johnson Trading Down 1.1%

NYSE:JNJ opened at $190.38 on Friday. The stock's 50 day moving average price is $182.26 and its 200 day moving average price is $166.13. The company has a market capitalization of $458.69 billion, a PE ratio of 18.38, a P/E/G ratio of 2.26 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.